Table 1. Participant characteristics.
| Characteristic | HITTINa, N = 17* | HITb, N = 11* | p-value** |
|---|---|---|---|
| Age | 43.71 (6.43) | 44.09 (6.89) | 0.9 |
| Sex | 0.6 | ||
| Female | 13 / 17 (76%) | 10 / 11 (91%) | |
| Male | 4 / 17 (24%) | 1 / 11 (9.1%) | |
| Weight | 75.81 (17.26) | 84.09 (18.12) | 0.3 |
| (Missing) | 1 | 0 | |
| Height | 1.63 (0.09) | 1.67 (0.06) | 0.2 |
| BMI c | 28.87 (7.38) | 30.15 (5.70) | 0.3 |
| (Missing) | 1 | 0 | |
| Time on ART d | 0.2 | ||
| Average time in years | 7.35 (3.15) | 8.97 3.2) | |
| CD4 prior to starting ART d | 0.4 | ||
| < 200 CD4+ cells/mm3 | 17 / 17 (100%) | 10 / 11 (91%) | |
| Between 200–350 CD4+ cells/mm3 | 0 / 17 (0%) | 1 / 11 (9.1%) | |
| Last CD4 prior to enrolment | 557.76 (229.70) | 486.73 (236.91) | 0.5 |
| Last VL e | 0.9 | ||
| ≤100 | 4/ 17 (24%) | 4 / 11 (36%) | |
| 124 | 1 / 17 (5.9%) | 0 / 11 (0%) | |
| LDLf | 12 / 17 (71%) | 7 / 11 (64%) | |
| Current IPT g | 1 / 17 (5.9%) | 0 / 11 (0%) | >0.9 |
| Previous IPT treatment as per months of treatment | 0.2 | ||
| 0 | 2 / 17 (12%) | 3 / 11 (27%) | |
| 2 | 0 / 17 (0%) | 1 / 11 (9.1%) | |
| 3 | 0 / 17 (0%) | 0 / 11 (0%) | |
| 4 | 0 / 17 (0%) | 0 / 11 (0%) | |
| 6 | 0 / 17 (0%) | 2 / 11 (18%) | |
| 12 | 10 / 17 (59%) | 5 / 11 (45%) | |
| 24 | 1 / 17 (5.9%) | 0 / 11 (0%) | |
| 36 | 3 / 17 (18%) | 0 / 11 (0%) | |
| Current | 1 / 17 (5.9%) | 0 / 11 (0%) | |
| Chronic Illness | 2 / 17 (12%) | 3 / 11 (27%) | 0.4 |
| Alcohol Use | 7 / 17 (41%) | 2 / 11 (18%) | 0.2 |
| Smoker | 2 / 17 (12%) | 0 / 11 (0%) | 0.5 |
| Recreational Substance (Cannabis) use | 0 / 17 (0%) | 1 / 11 (9.1%) | 0.4 |
*Mean (SD); n / N (%)
**Wilcoxon rank sum test; Fisher’s exact test
a HITTIN (HIV-1-infected persistently TB, tuberculin and IGRA negative)
b HIT (HIV-1-infected IGRA positive tuberculin positive)
c BMI (body mass index) was calculated as weight (kg)/height2(m)
d ART (antiretroviral therapy)
e VL (viral load)
f LDL (lower than detectable level)
g IPT (Isoniazid preventive therapy)